Our Clinical Trials

REASSERT: Advancing Research in Chronic Spontaneous Urticaria

Led at our center by principal investigator Christopher D. Codispoti, MD, PhD, REASSERT is an international observational study evaluating the effectiveness and safety of remibrutinib in adults with chronic spontaneous urticaria, a condition that causes recurring hives, swelling, or both. Participants are followed for 24 months to assess symptom control and quality of life during routine clinical care.

Learn more about REASSERT (external link).